The Federal Circuit recently reversed a district court decision that found a patent that did not describe after-arising technology failed to ...

For present purposes, the claims of the ‘659 Patent called for a pharmaceutical combination comprising valsartan and sacubitril “administered in combination” in about a 1:1 ratio.

Because the proposed generic drug accused of infringement was a “complex” of bonded valsartan ... sacubitril, the patentee Novartis needed to urge and had successfully urged that ...

This year has seen the US FDA approve 45 new chemical or biologic new entities, exceeding last year's tally of 40, and showing a continued resurgence in the pharma sector's R&D productivity.

Entresto (sacubitril+valsartan) was FDA-approved in patients ... to determine whether Verquvo is superior to placebo, both in combination with other heart failure therapies, in reducing the ...

Novartis AG NVS, a Swiss pharma giant, is scheduled to report fourth-quarter 2024 and full-year results on Jan. 31, 2025. The company’s earnings surpassed estimates in each of the trailing four ...

In the PARAGON-HF trial, in which women were enrolled at an increased rate, sacubitril/valsartan was shown to reduce the likelihood ... 25% of heart transplant recipients in the U.S., due to a ...

Global pharma major Lupin Limited (Lupin) announced that it has received United States Food and Drug Administration (FDA) approval for its Abbreviated new Drug Application (ANDA), sacubitril and ...